Articles by Syed Rabbani (5)

Gut Stimulatory Effect of Terminalia chebula in Experimental Animal Models

Vijayamahantesh K. Tandur, Mohammed Naseeruddin Inamdar, Abdulhakeem Alamri, Majid Alhomrani, Walaa F. Alsanie, Syed Imam Rabbani and Syed Mohammed Basheeruddin Asdaq

International Journal of Pharmacology 18 ( 7 ): 1466 - 1473 , 2022

Safety Analysis of Antiviral Drugs Approved for COVID-19 in Saudi Arabia

Syed Mohammed Basheeruddin Asdaq, Muath Mousa Almutairi, Marwan Suleiman Alharbi, Faisal Ghazi Alharbi, Abdullah Abdulrahman Alharbi, Saleh Saud Al-Harbi, Ali Ibrahim Almoteer, Ahmad Alenazi, Abdullah Saud Altayar, Raed Alharbi, Awwadh Alqarni, Bader Hussain Alamer, Ebtesam Abdulrahman Jibreel, Syed Arif Hussain and Syed Imam Rabbani

International Journal of Pharmacology 19 ( 4 ): 585 - 594 , 2023

A Preclinical Study to Evaluate the Spasmolytic Activity of Piper longum, Piper nigrum, Terminalia bellerica, Terminalia chebula and Zingiber officinale

Bansilal R. Tiwari, Mohammed Naseeruddin Inamdar, Mansour Almuqbil, Moneer E. Almadani, Mohammad Al Zahrani, Ebtesam Abdul Rahman Jibreel, Syed Arif Hussain, Syed Imam Rabbani and Syed Mohammed Basheeruddin Asdaq

International Journal of Pharmacology 19 ( 5 ): 665 - 672 , 2023

Ibuprofen with Amino Acid Dipeptide Conjugation: A Novel Prodrug for the Management of Alzheimer’s Disease Complications

Anjali Nayak, Rashu Raju, Paramita Das, Saad Alobid, Kuntal Das, A. Suvitha, Debashis Barik, Ali Ibrahim Almoteer, Syed Imam Rabbani, B.P. Mallikarjuna, Naira Nayeem, Rafiulla Gilkaramenthi and Syed Mohammed Basheeruddin Asdaq

International Journal of Pharmacology 20 ( 1 ): 62 - 71 , 2024

Potential Anti-Diabetic Benefits of Momordica charantia Extracts on Experimental Diabetes and its Complications

Vinay Basavanakatti, Mohammed Naseeruddin Inamdar, Saad Alobid, Mohammed Sharique Ahmed Quadri, Sultan Alshehri, Syed Imam Rabbani, Rafiulla Gilkaramenthi, Ali Ibrahim Almoteer and Syed Mohammed Basheeruddin Asdaq

International Journal of Pharmacology 20 ( 1 ): 81 - 91 , 2024